Menu
Search
|

Menu

Close
X

Arrowhead Pharmaceuticals Inc ARWR.OQ (NASDAQ Stock Exchange Global Select Market)

16.41 USD
+0.00 (+0.00%)
As of Jul 14
chart
Previous Close 16.41
Open 16.41
Volume 276,130
3m Avg Volume 537,943
Today’s High 16.48
Today’s Low 16.01
52 Week High 16.64
52 Week Low 1.48
Shares Outstanding (mil) 74.77
Market Capitalization (mil) 317.78
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
31
FY16
0
FY15
0
EPS (USD)
FY18
-0.353
FY17
-0.467
FY16
-1.338
FY15
-1.605
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
13.98
5.73
Price to Book (MRQ)
vs sector
3.53
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
2.87
16.72
LT Debt to Equity (MRQ)
vs sector
2.64
12.39
Return on Investment (TTM)
vs sector
-55.08
14.61
Return on Equity (TTM)
vs sector
-61.13
16.34

EXECUTIVE LEADERSHIP

Douglass Given
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Christopher Anzalone
President, Chief Executive Officer, Director, Since 2007
Salary: $614,051.00
Bonus: $448,594.00
Kenneth Myszkowski
Chief Financial Officer, Since 2010
Salary: $333,178.00
Bonus: $130,524.00
Bruce Given
Chief Operating Officer, Since 2011
Salary: $430,835.00
Bonus: $251,796.00
Patrick O'Brien
General Counsel, Since 2015
Salary: $389,708.00
Bonus: $170,820.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

225 S Lake Ave Ste 1050
PASADENA   CA   91101-4820

Phone: +1626.3043400

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

SPONSORED STORIES